drugset
drugset / Trial / NCT00621517

Bupropion and Restless Legs Syndrome

NCT00621517 ↗

Phase 2/3 Completed 60 enrolled East Tennessee State University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if bupropion will improve the symptoms of restless legs syndrome (RLS).

Timeline

Start
2008-02
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg —

Indications

restless legs syndrome